X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
MN-001 (tipelukast) is a novel, leukotriene receptor antagonist which inhibits phosphodiesterase and 5-lipoxygenase and is believed to reduce inflammation and prevent fibrosis. It received a notice of allowance for a new patent for treating advanced NASH in Canada.
Lead Product(s): Tipelukast
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MN-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2023
Details:
MN-001 (tipelukast) is a novel, orally administered, small molecule compound which reduces triglycerides (TG) in the blood. It has being investigated for the treatment or maintainence of type 2 diabetes and hypertriglyceridemia.
Lead Product(s): Tipelukast
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MN-001
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2023
Details:
MN-001 (tipelukast), is a novel, orally administered, small molecule leukotriene receptor antagonist which inhibits phosphodiesterase (mainly 3 and 4) and 5-lipoxygenase (5-LO) and is believed to reduce inflammation and prevent fibrosis.
Lead Product(s): Tipelukast
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MN-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
MN-001 (tipelukast), an orally administered, small molecule compound with multiple mechanisms of action which has been in clinical development for the treatment of chronic inflammatory and fibrotic diseases, among others, due to its anti-inflammatory and anti-fibrosis effects.
Lead Product(s): Tipelukast
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MN-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
Details:
MN-001 (tipelukast) is small molecule compound thought to exert effects through mechanisms to produce its anti-inflammatory and anti-fibrotic activity in preclinical models, including LT receptor antagonism, inhibition of phosphodiesterases, and inhibition of 5-lipoxygenase.
Lead Product(s): Tipelukast
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MN-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2022
Details:
MN-001 (tipelukast) is a novel, orally bioavailable, small molecule compound thought to exert its effects through several mechanisms to produce its anti-inflammatory and anti-fibrotic activity in preclinical models, including leukotriene (LT) receptor antagonism.
Lead Product(s): Tipelukast
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MN-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Juntendo University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 22, 2022
Details:
Results from Phase 2a study in NASH/NAFLD patients with hypertriglyceridemia in which MN-001(tipelukast) was shown to reduce serum triglycerides, increase high-density lipoproteins (HDL-C), and reduce low-density lipoproteins during 12-week treatment period.
Lead Product(s): Tipelukast
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MN-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2022
Details:
Allowed claims cover MN-001 (tipelukast), small molecule compound thought to exert its effects through several mechanisms to produce its anti-inflammatory and anti-fibrotic activity in preclinical models and MN-002 for treatment of a patient with advanced NASH.
Lead Product(s): Tipelukast
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MN-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Korean Intellectual Property Office
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2022
Details:
The allowed claims cover a pharmaceutical composition comprising MN-001 (tipelukast) for reducing a triglyceride blood level, reducing a total cholesterol blood level, and reducing a low-density lipoprotein (LDL) blood level.
Lead Product(s): Tipelukast
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MN-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2022
Details:
MN-001 (tipelukast) is a novel, orally bioavailable, small molecule compound thought to exert its effects through several mechanisms to produce its anti-inflammatory and anti-fibrotic activity in preclinical models.
Lead Product(s): Tipelukast
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MN-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2022
Details:
The study sought to examine the pathogenic role of phosphodiesterase 4 (PDE4) in hepatic stellate cell (HSC) activation and TGFβ1 (transforming growth factor beta 1) signaling. TGFβ1 induced HSC activation.
Lead Product(s): Tipelukast
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: MN-001
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute of General Medical Sciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2020
Details:
MN-001 is a novel, orally bioavailable, small molecule compound thought to produce its anti-inflammatory and anti-fibrotic activity in preclinical models, including leukotriene receptor antagonism, inhibition of phosphodiesterases, and inhibition of 5-lipoxygenase.
Lead Product(s): Tipelukast
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MN-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
MediciNova has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (metabolite of MN-001) for the treatment of hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia.
Lead Product(s): Tipelukast
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MN-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2020
Details:
The allowed claims cover MN-001 and MN-002 for use in the treatment of a patient with advanced NASH.
Lead Product(s): Tipelukast
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 17, 2020
Details:
The allowed claims cover the use of MN-001 for treating a patient diagnosed with idiopathic pulmonary fibrosis.
Lead Product(s): Tipelukast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
